Active-site mTOR inhibitors (asTORi) hold great promise for targeting dysregulated mTOR signaling in cancer. Because of the multifaceted nature of mTORC1 signaling, identification of reliable biomarkers for the sensitivity of tumors to asTORi is imperative for their clinical implementation. Here, we show that cancer cells acquire resistance to asTORi by downregulating eukaryotic translation initiation factor (eIF4E)-binding proteins (4E-BPs-EIF4EBP1, EIF4EBP2). Loss of 4E-BPs or overexpression of eIF4E renders neoplastic growth and translation of tumor-promoting mRNAs refractory to mTOR inhibition. Conversely, moderate depletion of eIF4E augments the anti-neoplastic effects of asTORi. The anti-proliferative effect of asTORi in vitro and in vivo is therefore significantly influenced by perturbations in eIF4E/4E-BP stoichiometry, whereby an increase in the eIF4E/4E-BP ratio dramatically limits the sensitivity of cancer cells to asTORi. We propose that the eIF4E/4E-BP ratio, rather than their individual protein levels or solely their phosphorylation status, should be considered as a paramount predictive marker for forecasting the clinical therapeutic response to mTOR inhibitors. Cancer Res; 72(24); 6468-76. Ó2012 AACR.
Introduction
mTOR is a multifunctional serine/threonine kinase, which exists in 2 distinct complexes, mTOR complex 1 and 2 (mTORC1 and 2; ref. 1). mTORC1 governs many cellular processes including mRNA translation, cell growth, and proliferation, by phosphorylating downstream targets such as 4E-BPs and S6Ks (1) . mTORC2 controls cell survival and cytoskeleton organization by modulating the activity of AGC kinases (e.g., Akt and SGK1) and regulates nascent polypeptide stability (2) . Hyperactivation of mTOR signaling frequently occurs in cancer (in more than 70% of patients; ref. 3 ). Therefore, targeting mTOR represents one of the most attractive anti-cancer therapeutic strategies. Rapamycin, a naturally occurring allosteric inhibitor of mTORC1, and its analogues (rapalogs), are clinically approved for treatment of renal cell carcinomas, mantle cell lymphomas, and pancreatic neuroendocrine tumors (4, 5) . Nonetheless, the overall success of rapalog monotherapies is limited. This has been attributed to the incomplete inhibition of mTORC1-mediated phosphorylation of 4E-BPs, and the activation of Akt via the loss of a negative feedback mechanism (4, 6, 7) . Recently, asTORi (also referred to as TORKin or dual mTORC1/mTORC2 inhibitors) were developed to overcome these issues. asTORi abolish phosphorylation of 4E-BPs via the inhibition of mTORC1, suppress Akt signaling via the inhibition of mTORC2, and exhibit stronger anti-proliferative and anti-tumorigenic effects than rapamycin (8) (9) (10) (11) . However, mTOR regulates various cancer-related processes via a multitude of substrates, and this complexity of mTOR signaling represents a significant challenge for identifying surrogate biomarkers that could serve to predict the efficacy of asTORi in the clinic (12) . eIF4E is the 5 0 mRNA cap-binding subunit of the eIF4F complex, which recruits mRNA to the ribosome. eIF4F also includes the large scaffolding protein eIF4G and the DEAD-box RNA helicase eIF4A (13, 14) . 4E-BPs (in mammals 4E-BP1, 2, and 3) are small-molecular-weight translational repressors, which impair the assembly of the eIF4F complex by competing with eIF4G for binding to eIF4E (14, 15) . mTORC1 phosphorylates 4E-BPs leading to their dissociation from eIF4E, thus increasing the amount of eIF4E available to engage in the eIF4F complex assembly (15) (16) (17) . Ectopic expression of eIF4E leads to transformation of immortalized rodent and human cells (18, 19) and is tumorigenic in vivo (20) . About 30% of cancers exhibit elevated eIF4E levels, which correlate with poor prognosis (21) . eIF4E overexpression induces cell transformation by selectively augmenting translation of mRNAs referred to as eIF4E-sensitive mRNAs, which encode proliferation-and survival-promoting proteins (e.g., cyclins, c-myc, and Bcl-xL; refs. 18, 22) . Multiple factors can induce the overexpression of eIF4E in cancer cells including gene amplification (23) , transcriptional upregulation by c-myc (24) , and increase in eIF4E mRNA stability by HuR (25) . Dysregulated expression and/or increased phosphorylation of 4E-BPs in cancer have also been linked to poor patient outcomes (21, 26) . 4E-BPs mediate the effects of mTOR signaling on translation of mRNAs that encode proteins that are associated with cancer progression, invasion, and metastasis (e.g., Y-box protein 1, vimentin, and CD44; ref. 11). 4E-BP1 expression is controlled at the transcriptional and protein stability levels by ATF4 (27) and the KLHL25-CUL3 complex (28) , respectively.
In this study, we show that cancer cells acquire resistance to asTORi by increasing eIF4E availability via downregulation of 4E-BP1 and 2. Accordingly, we show that an increase in eIF4E, or reduction in 4E-BP levels by RNA interference, strongly attenuates the anti-neoplastic effects of the asTORi PP242, Torin1, and INK1341 (an analogue of the recently characterized INK128 compound; ref. 11). Conversely, a decrease in the eIF4E/4E-BP ratio ameliorates the inhibitory effects of asTORi on translation of eIF4E-sensitive cyclin D3 and E1 mRNAs. Thus, the eIF4E/4E-BP ratio in the tumor could be a significant predictive marker of the efficacy of asTORi that should be considered in devising personalized asTORi treatments.
Materials and Methods
Cell culture, constructs, viral infections, and lentiviral shRNA silencing E1A/Ras-transformed WT (p53 À/À ) and 4E-BP1/2 DKO (p53
) mouse embryonic fibroblasts (MEF), referred to as WT E1A/Ras and 4E-BP1/2 DKO E1A/Ras MEFs respectively, were previously described (7). HeLa, SK-HEP-1, and HepG2 cells were directly purchased from and authenticated by American Type Culture Collection. Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen), supplemented with 10% FBS (Invitrogen), 2 mmol/L L-glutamine, and 100 units/mL penicillin/streptomycin (all from Invitrogen) at 37 C and 5% CO 2 . To induce acquired resistance to asTORi, WT E1A/Ras , HepG2 and SK-HEP-1 cell lines were cultured in the continuous presence of the PP242 (1 mmol/L for 8 weeks). NIH3T3 cells transduced with pMV7-eIF4E or empty vector (pMV7) were described previously (18) . For overexpression studies, pcDNA3-3HA-4E-BP1 (4E-BP1 WT ) and pACTAG2-3HA-4E-BP1 (4E-BP1 D4E ) have been described previously (29, 30) . 4E-BP1 and mutant cDNA were amplified by PCR and inserted into BamHI/SalI sites of the retroviral vector pBABE. Cell lines that stably express 4E-BP1 were generated as described previously (31) . Briefly, pBABE constructs were transiently transfected into the Ecotropic Phoenix-293T packaging cell line. After 48 hours, virus-containing medium was filtered (0.45 mm), collected, and used to infect MEFs in the presence of 5 mg/mL polybrene (Sigma-Aldrich). Infection was repeated the next day. Twenty-four hours after the second infection, medium supplemented with puromycin (1 mg/mL, Sigma-Aldrich) was added, and cells were subjected to selection for 1 week, after which time colonies were pooled. pcDNA3-FLAG-eIF4E
WT and eIF4E W56A (cap-binding mutant) were constructed by cloning the entire coding sequence of mouse eIF4E into pcDNA3-FLAG using a PCR (32) . These vectors were transfected and cells selected in G418 for 2 weeks. Lentiviral vectors were from Sigma. Short hairpin RNA (shRNA) vector accession numbers are: mouse eIF4E (Sigma: TRCN0000077474), the Non-Target shRNA Control (Sigma: SHC002). shRNA vectors were co-transfected into HEK293T cells with the lentivirus packaging plasmids PLP1, PLP2, and PLP-VSVG (Invitrogen) using Lipofectamine 2000 (Invitrogen). Supernatants were collected 48 and 72 hours posttransfection, passed through a 0.45-mm nitrocellulose filter, and applied on target cells with polybrene (5 mg/mL). Cells were re-infected the next day and selected with puromycin for 48 hours (1 mg/mL, Sigma). PP242 and INK1341 were provided by Intellikine. Torin1 was from N. Gray and D. Sabatini.
Cell-cycle analysis and apoptosis
Cells were seeded in 100-mm dishes, grown overnight, and treated as indicated in figure legends. Twenty-four or 48 hours later, cells were harvested by trypsinization, washed twice with PBS containing 2% FBS and once in PBS. For cell-cycle analysis, cells were resuspended in 200 mL of NPE Nuclear Isolation Media (NIM)-DAPI (Beckman Coulter) and analyzed using a Cell Lab Quanta SC (Beckman Coulter) flow cytometer. For apoptosis, cells were analyzed by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit according to the manufacturer's protocol (Bio Vision).
Cell proliferation, soft agar, and anchorage-dependent foci formation assay For the bromodeoxyuridine (BrdU) incorporation assay (Cell Proliferation ELISA BrdU Kit from Roche), cells were seeded in 96-well plates (1,000 cells/well) and maintained as indicated in the figure legends. Absorbance at 370 nm (reference wavelength ¼ 492 nm) was measured using a Varioskan microplate reader (Thermo Electron Corporation). For Trypan blue exclusion, cells were seeded in 6-well plates (50,000 cells/ well) overnight and maintained under conditions outlined in the figure legends. Cell proliferation was determined by direct counting (dead cells were excluded by Trypan blue staining). For soft agar assays, experiments were carried out in 6-well plates coated with a base layer of 0.5% agarose (Agar Noble, Difco). WT E1A/Ras and 4E-BP1/2 DKO E1A/Ras MEFs were seeded in triplicates at a density of 5,000 cells/well in 0.35% agarose containing either vehicle [dimethyl sulfoxide (DMSO)], PP242 (1 mmol/L), or INK1341 (250 nmol/L). Cells were overlaid with DMEM supplemented with 10% FBS, 2 mmol/L L-glutamine, and 100 units/mL penicillin/streptomycin (Invitrogen) containing either DMSO, PP242 (1 mmol/L), or INK1341 (nmol/L), and incubated for up to 10 to 14 days. Media containing vehicle, PP242, or INK1341 were changed every 3 to 4 days during the course of the experiment. Colonies were counted using a light microscope. For focus formation assays, cells were seeded at a density of 10,000 cells/10-cm dish and allowed to grow in the presence of either vehicle (DMSO) or PP242 (1 mmol/L) or INK1341 (250 nmol/L). Media containing drugs were changed as above every 3 to 4 days.
Western blot analysis and cap (m 7 GDP) pull-down assay Cell lysates were prepared, and Western blotting was carried out as described (33) . Antibodies against 4E-BP1, 4E-BP2, phospho-4E-BP1 (Thr37/46, Ser65, Thr70), rpS6, phospho-rpS6 (Ser240/244), Akt, phospho-Akt (S473), eIF4G1, and cyclin D3 were from Cell Signaling Technology (Danvers, MA). Antibody against cyclin E1 was from Santa Cruz Biotechnology. Antibodies against eIF4E and b-actin were from Sigma. Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and antimouse IgG were from Amersham Biosciences. For cap-binding affinity assay, cells were lysed in the lysis buffer [50 mmol/L HEPES-KOH (pH 7.5), 150 mmol/L KCL, 1 mmol/L EDTA, 2 mmol/L dithiothreitol (DTT), and 0.2% Tween] containing protease inhibitors. Cell lysates were incubated with m 7 GDPagarose and washed 4 times using the lysis buffer. m 7 GDPbound proteins were determined by Western blotting.
Polysome analysis, RNA isolation, and sqRT-PCR
Polysome profile analysis was carried out as previously described (34) . Briefly, cells were cultured in 15-cm dishes and treated with PP242 (1 mmol/L), INK1341 (250 nmol/L), or vehicle (DMSO) for 8 hours. Cells were washed with cold PBS containing 100 mg/mL cycloheximide, collected, and lysed in a hypotonic lysis buffer [5 mmol/L Tris-HCl (pH 7.5), 2.5 mmol/L MgCl 2 , 1.5 mmol/L KCl, 100 mg/mL cycloheximide, 2 mmol/L DTT, 0.5% Triton X-100, and 0.5% sodium deoxycholate). Lysates were loaded onto 10% to 50% sucrose density gradients [20 mmol/L HEPES-KOH (pH 7.6), 100 mmol/L KCl, 5 mmol/L MgCl 2 ] and centrifuged at 36,000 rpm for 2 hours at 4 C. Gradients were fractionated, and the optical density (OD) at 254 nm was continuously recorded using an ISCO fractionator (Teledyne ISCO). RNA from each fraction was isolated using TRIzol (Invitrogen) and treated with DNaseTurbo (Ambion) according to the manufacturer's instructions. Reverse transcription PCR (RT-PCR) and quantitative RT-PCR (qRT-PCR) reactions were carried out using SuperScript III First-Strand Synthesis System (Invitrogen) and iQ SYBR Green Supermix (BIO-RAD) according to the manufacturer's instructions. The list of primers and the number of cycles used for each of the transcripts were described (7).
Tumor growth curves
Six-to 8-week-old Nude NCR (nu/nu) mice were obtained from Taconic. The animals were maintained under specific pathogen-free conditions and treated according to a protocol approved by the McGill University Animal Care Committee (Montreal, QC, Canada). A total of 5 Â 10 6 WT E1A/Ras and 4E-BP1/2 DKO E1A/Ras MEFs in 100 mL PBS were injected in the hind flank of the mice and allowed to grow until palpable tumors were established. For drug treatment, PP242 at 60 mg/kg in a solution containing 40% PEG-400, 40% PBS, and 20% DMSO was administrated intraperitoneally in 100 mL volume. Two-dimensional tumor measurements were conducted with calipers every other day for 10 days or until the animals showed severe complications due to excess tumor burden.
Statistical analysis
Error bars for all data represent SDs from the mean. P values were calculated using Student t tests.
Results

Acquired resistance to asTORi coincides with downregulation of 4E-BP1 and 2 expression
To investigate the potential mechanism of acquired resistance to asTORi in cancer cells, we cultivated E1A/Ras-transformed p53 À/À MEFs (WT E1A/Ras ) and 2 liver cancer cell lines (HepG2 and SK-HEP-1) in the presence of the asTORi PP242 (1 mmol/L for 8 weeks). Strikingly, all 3 cell lines acquired resistance to PP242, which correlated with a downregulation of 4E-BP1 and 2 (Figs. 1A-C; Supplementary Fig. S1A-S1F ), but not with a loss of mTORC1 or 2 inhibition, inasmuch as asTORi induced similar suppression of ribosomal protein S6 (S6) and Akt phosphorylation in resistant and control cells (Supplementary Fig. S1G and S1H).
To ascertain that 4E-BPs are responsible for the anti-neoplastic activity of asTORi, we investigated the effects of PP242 on the neoplastic growth of WT E1A/Ras and E1A/Ras-transformed p53
MEFs are devoid of all 4E-BPs, as MEFs do not express 4E-BP3 (7). WT E1A/Ras and 4E-BP DKO E1A/Ras MEFs proliferated at the same rate in full growth medium (Fig. 1D) where mTOR activity is high and 4E-BP1 and S6 are hyperphosphorylated (Fig. 1E) . However, while PP242 inhibits mTORC1 signaling to a similar extent in these cells, as illustrated by a comparable reduction in the phosphorylation of S6 (Fig. 1E) , the effects of PP242 on neoplastic growth were significantly less pronounced in 4E-BP DKO E1A/Ras MEFs ($45% reduction in number of colonies and foci relative to control) than in WT E1A/Ras MEFs ($70%; Figs. 1F and G; Supplementary Fig.  S2A-S2C ). Moreover, depletion of 4E-BP1 and 2 rendered neoplastic growth of SK-HEP-1 and HepG2 cells partially resistant to PP242 (Supplementary Figs. S1A-S1C and S2D-S2F). These results show that loss of 4E-BPs attenuates the anti-neoplastic efficacy of asTORi.
Increased eIF4E availability renders cells resistant to asTORi
When mTOR signaling is inhibited, 4E-BPs limit the fraction of eIF4E available for the assembly of the eIF4F complex (15) (16) (17) . Thus, we investigated whether the sequestration of eIF4E by 4E-BPs is required for the anti-neoplastic activity of INK1341 by overexpressing 4E-BP1
WT and 4E-BP1 D4E mutant, which lacks the eIF4E-binding motif and thus cannot bind eIF4E (ref. 35 ; Fig.  1H ). Expression of 4E-BP1
WT , but not 4E-BP1
D4E
, augmented the anti-neoplastic effect of INK1341 (Figs. 1I and J) . Moreover, forced expression of 4E-BP1
WT markedly reduced the association between eIF4E and eIF4G1 as compared with a control ( Supplementary Fig. S2G and S2H ). Taken together, these results show that 4E-BPs mediate the anti-tumorigenic activity of asTORi by limiting the availability of eIF4E to associate with eIF4G1, thereby impeding the eIF4F complex assembly. eIF4E is frequently overexpressed in cancer (21) . We examined whether overexpression of eIF4E, akin to loss of 4E-BPs, alleviates the anti-proliferative effects of the asTORi, Supplementary Fig. S3A ). In contrast, Torin1 inhibited proliferation and G 1 to S-phase cell-cycle progression in NIH3T3/4E cells to a dramatically lesser extent ($15%) as compared with control cells ($85%; Supplementary Fig. S3B and S3C). Figure 2 . Elevated eIF4E/4E-BP ratio diminishes the anti-proliferative effects of asTORi. A, phase contrast images of WT E1A/Ras MEFs transduced with scrambled (Scr) or eIF4E shRNA (eIF4E KD; top). Proliferation rates of the indicated cells in full growth medium were determined by Trypan blue exclusion (bottom). Results are presented as mean numbers of cells AE SD (n ¼ 3). B, cells described in A were treated with DMSO or PP242 (1 mmol/L) for 3 hours, and the levels and the phosphorylation status of indicated proteins were determined by Western blot analysis. b-Actin served as a loading control. C, effects of DMSO or PP242 (1 mmol/L) on anchorage-independent growth of cells described in A were monitored using a soft agar assay. Colonies in soft agar were counted after 10 days. Results are presented as a mean number of colonies relative to DMSO-treated cells (set to 100%) AE SD (n ¼ 3). D, representative photographs of colonies formed by cells described in A. E, WT E1A/Ras MEFs transduced with scrambled (WT E1A/Ras þ Scr) or eIF4E shRNA (WT E1A/Ras þ eIF4E KD) and 4E-BP DKO E1A/Ras MEFs were treated with PP242 (1 mmol/L) or INK1341 (250 nmol/L) for 3 hours. Levels of the indicated proteins were determined by Western blot analysis. b-Actin served as a loading control. F, effects of DMSO and INK1341 (250 nmol/L) on anchorageindependent growth of cells described in E were monitored using a soft agar assay. Colonies were counted after 10 days of treatment. Results represent the mean colony number relative to a DMSO control (set to 100%) AE SD (n ¼ 3). G, representative photographs of colonies formed by cells described in E. H, WT E1A/Ras MEFs were transfected with an empty vector (pcDNA3.1) or vector expressing Flag-tagged wild type (eIF4E WT ) or a cap-binding mutant of eIF4E (eIF4E W56A ). Levels of the indicated proteins were determined by Western blot analysis. b-Actin served as a loading control. Arrows indicate exogenous Flag-tagged (Flag-eIF4E) and endogenous eIF4E. I, effect of DMSO or PP242 (1 mmol/L) on anchorage-independent growth of cells described in H was monitored using soft agar assay. Colonies were counted after 10 days of treatment. Results represent the mean cell number relative to a DMSO control (set to 100%) AE SD (n ¼ 3). J, representative photographs of colonies formed by cells described in H.
A B C E F G H I J
To further establish that the alterations in eIF4E availability determine the anti-neoplastic effects of asTORi, we depleted eIF4E in WT E1A/Ras MEFs and compared the anti-neoplastic effects of PP242 with those observed in control cells. As significant eIF4E downregulation inhibits proliferation and survival (36), we selected cells in which eIF4E depletion ($50% of control) does not affect cell proliferation under optimal nutrient conditions wherein mTOR is active ( Fig.  2A and B) . Nonetheless, an approximate 50% decrease in eIF4E levels strongly augmented the sensitivity of WT E1A/Ras MEFs to PP242 ($85% reduction in colony and foci formation), as compared with control ($65%; Figs. 2C and D; Supplementary  Fig. S3D-S3F) . Similar results were obtained using INK1341 (Figs. 2E-G; Supplementary Fig. S3G and S3H) . Suppression of neoplastic growth by asTORi was caused by the inhibition of cell-cycle progression from G 1 to S-phase, whereas asTORi did not exert a major effect on cell survival ( Supplementary Fig.  S4A-S4C) . Importantly, the asTORi-induced inhibition of G 1 -S progression was alleviated in cells with high eIF4E/4E-BP ratio (Supplementary Fig. S4A ). These results support a model whereby asTORi suppress neoplastic growth by limiting eIF4E availability and cell-cycle progression.
Persistent translation of eIF4E-sensitive mRNAs renders cells refractory to asTORi
The eIF4E/4E-BP ratio dictates cap-dependent mRNA translation rates (15) . Thus, we investigated whether translational activity of eIF4E is required for attenuation of the anti-neoplastic effects of asTORi, by overexpressing wild-type (eIF4E WT ) and a translationally inactive W56A eIF4E mutant (eIF4E W56A ; refs. 37, 38) in WT E1A/Ras MEFs. Both proteins were expressed to a comparable level (Fig. 2H) . Cells overexpressing WT exhibited significantly lower sensitivity ($50% inhibition of proliferation) to the anti-neoplastic and anti-proliferative effects of PP242 than control cells ($70%), whereas suppression of proliferation and neoplastic growth by PP242 in cells overexpressing eIF4E
W56A was similar to that observed in control cells (Figs. 2I and J; Supplementary Fig. S4D and S4E) . Similar results were obtained in HeLa cells ( Supplementary  Fig. S4F-S4H) .
Next, we examined the effect of PP242 and INK1341 on global mRNA translation in WT E1A/Ras and 4E-BP DKO
E1A/Ras
MEFs, as well as in WT E1A/Ras MEFs depleted of eIF4E, by studying polysome formation. The fraction of ribosomes engaged in polysomes is directly proportional to the translation initiation rate (39) . Consistent with previous reports that PP242 suppresses initiation of cap-dependent mRNA translation (8), a decrease in the number of ribosomes engaged in polysomes, and a concomitant increase in 80S monosome peak was detected in all cells treated with PP242 as compared with control (Fig. 3A) . However, inhibition of polysome formation by PP242 was most pronounced in WT E1A/Ras MEFs in which eIF4E was depleted, intermediate in control WT E1A/Ras MEFs, and weakest in 4E-BP DKO E1A/Ras MEFs (Fig. 3A) . Similar results were obtained using INK1341 (Fig. 3B) .
While our data show that an elevated eIF4E/4E-BP ratio mitigates the inhibition of global mRNA translation by PP242 or INK1341, the lack of a complete dissociation of polysomes indicates that the majority of mRNAs remain translationally active in asTORi-treated cells. This suggests that the resistance to asTORi is caused by the resistance of eIF4E-sensitive mRNAs to inhibition in cancer cells with elevated eIF4E/4E-BP ratio (21, 40) . Thus, we investigated the effects of PP242 and INK1341 on translation of the prototypical eIF4E-sensitive mRNAs cyclin D3, and cyclin E1, as well as ß-actin mRNA, which is only marginally sensitive to changes in eIF4E (7, 22) . In vehicle-treated cells, in which the sequestration of eIF4E by 4E-BPs is minimal due to the hyperphosphorylation of 4E-BPs, loss of 4E-BPs or approximately 50% depletion of eIF4E had no major impact on translation of eIF4E-senstive mRNAs (Figs. 3C-E). PP242 and INK1341 abolished the phosphorylation of 4E-BPs (Figs. 1E, 2B , and 3E) and strongly suppressed translation of the eIF4E-sensitive mRNAs cyclin D3 and E1, as well as the expression of corresponding proteins in control $20 mm 2 ), mice were injected intraperitoneally with vehicle or PP242 (60 mg/kg) daily for 10 days. Tumor growth was followed every second day, and 2-dimensional measurements were taken using a caliper. C and D, nude NCR mice were subcutaneously implanted with 5 Â 10 6 WT E1A/Ras MEFs infected with scrambled (Scr) or eIF4E shRNA (eIF4E KD) and treated as in A and B. E, photographs of representative tumors isolated from each group of mice. F, levels and the phosphorylation status of S6 and 4E-BP1 proteins at indicated time points in tumors described in A were determined by Western blot analysis. S6 served as loading control. Arrows indicate the hyperphosphorylated (hyper-P) and hypophosphorylated (hypo-P) forms of 4E-BP1. G, proposed model of cancer cell sensitivity to asTORi. asTORi induce sufficient sequestration of eIF4E to inhibit translation of eIF4E-sensitive mRNAs and neoplastic growth of cancer cells with low (left circle) but not high (right circle) eIF4E/4E-BP ratio.
WT
E1A/Ras MEFs, which was further potentiated by the depletion of eIF4E (Figs. 3C-E) . In stark contrast, translation of cyclin D3 and E1 mRNAs and expression of cyclin D3 and E1 proteins in 4E-BP DKO E1A/Ras MEFs were largely insensitive to PP242 and INK1341 (Figs. 3C-E) . As expected, the translation of b-actin mRNA or expression of b-actin protein were not influenced by asTORi treatment in any of the cell lines (Figs. 3C-E) . Finally, Torin1 strongly reduced cyclin D3 expression in control NIH3T3 cells, but not in NIH3T3 cells overexpressing eIF4E (Supplementary Fig. S3A ). Collectively, these results show that the resistance to the anti-neoplastic effects of asTORi of cancer cells with high eIF4E/4E-BP ratio stems from the failure of asTORi to efficiently inhibit translation of eIF4E-sensitive mRNAs.
eIF4E/4E-BP ratio determines sensitivity to asTORi in vivo Next, we studied the impact of perturbations in the eIF4E/ 4E-BP ratio on the anti-neoplastic activity of asTORi in vivo. Mice bearing subcutaneous tumors formed by WT E1A/Ras or 4E-BP DKO E1A/Ras MEFs were treated daily with PP242 or a vehicle. Remarkably, whereas PP242 inhibited the growth of tumors formed by WT E1A/Ras MEFs, tumors lacking 4E-BPs were completely resistant to PP242. Moreover, depletion of eIF4E in WT E1A/Ras tumors further increased their sensitivity to PP242 (Figs. 4A-E) . PP242 strongly inhibited mTOR signaling in vivo, as illustrated by inhibition of S6 phosphorylation 30 minutes and 24 hours postinjection from tumor tissues (Fig. 4F) . Thus, consistent with the in vitro findings, the anti-neoplastic activity of asTORi in vivo is predominantly established by the eIF4E/4E-BP ratio in the tumor.
Discussion
mTOR signaling is frequently dysregulated in cancer and is being targeted in clinical trials using asTORi (1, 41) . However, there are currently no reliable markers that can predict the therapeutic efficacy of asTORi. Recently, several models have been proposed to explain resistance to asTORi as well as dual PI3K/mTOR kinase inhibitors in tumors. These include activation of alternative signaling pathways, such as the extracellular signal-regulated kinase pathway that can render 4E-BP1 persistently inactive despite treatment with mTOR inhibitors (42) , or pathways that activate cap-independent translation of survival-promoting mRNAs (43) . We have unraveled a different mechanism to explain the acquired resistance to mTOR inhibitors, whereby cancer cells become insensitive to asTORi by downregulating expression of 4E-BP1 and 2. This leads to an increase in the eIF4E/4E-BP ratio, thereby attenuating the antineoplastic effects of asTORi as it limits their inhibitory effect on the translation of eIF4E-sensitive mRNAs. Our model explains recent findings showing that resistance to BEZ235, a dual PI3K/mTOR inhibitor, can be acquired through amplification of the eIF4E gene (44) . Thus, our results support a model whereby an elevated eIF4E/4E-BP ratio renders tumors resistant not only to asTORi (Fig. 4G ) but also to dual PI3K/mTOR inhibitors.
Recent studies have proposed that the combination of mitogen-activated protein kinase with mTOR inhibitors could overcome resistance to mTOR inhibitors (42, 45) . However, data presented here raise the possibility that using therapies that target eIF4E in the tumor (21, 36) may be more beneficial in cases where elevated eIF4E/4E-BP ratio is present. Moreover, our findings strongly suggest that the eIF4E/4E-BP ratio could serve as a predictive marker to tailor personalized treatments using asTORi in the clinic.
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